POST Online Media Lite Edition



 

Additional manufacturing capacity for BioNTech/Pfizer COVID-19 vaccine

Christian Fernsby |
EMA has recommended the approval of additional manufacturing and filling lines at Pfizer’s vaccine manufacturing site in Puurs, Belgium.

Article continues below



Topics: BIONTECH    PFIZER   

The recommendation by the Agency’s Committee for Human Medicines (CHMP) is expected to have a significant and immediate impact on the supply of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer, in the European Union.

Based on the review of the data submitted by BioNTech Manufacturing GmbH, EMA’s decision reaffirms that the Puurs facility is capable of consistently producing high-quality vaccines and enables Pfizer/BioNTech to increase the volumes of vaccines produced at this site.


What to read next

BioNTech to acquire plant in Germany to produce coronavirus vaccine
Pfizer and BioNTech share positive early data on mRNA vaccine candidate BNT162b2 against coronavirus
Sanofi to provide support to BioNTech in manufacturing their COVID-19 vaccine